NCT01324479已完成1 期
A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 131
- 试验地点
- 6
- 主要终点
- Incidence rate of dose-limiting toxicities and adverse events
研究概览
简要总结
This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have evidence of c-MET dysregulation from either local data or the results of molecular pre-screening evaluations.
- •Confirmed diagnosis of a solid tumor.
- •Measureable lesion.
- •Refractory to currently available treatment or no therapies available.
- •18 years or older.
- •ECOG performance status of 0, 1, or
- •Obtained written informed consent.
- •Additional inclusion criteria for NSCLC patients EGFRwt with high c-MET expression:
- •Written documentation of EGFRwt NSCLC.
- •Written documentation of c-MET positivity.
- •Patients should not have received more than three prior lines of antineoplastic therapy for NSCLC.
- •Presence of at least one measurable lesion as determined by modified RECIST version 1.1
排除标准
- •HCC with liver dysfunction greater than Child-Pugh A. Previous treatment with a c-MET inhibitor or HGF-targeting therapy. Symptomatic CNS metastases that are neurologically unstable or requiring increasing doses of steroids to control their CNS disease.
- •Any CNS deficits. For patients with GBM, CNS symptoms grade 2 or greater. Subjects with significant or uncontrolled cardiovascular disease (eg, uncontrolled hypertension, peripheral vascular disease, congestive heart failure, cardiac arrhythmia, or acute coronary syndrome) within 6 months of starting study treatment or heart attack within 12 months of starting study treatment.
- •Receiving anti-epileptic drugs that are known to be strong inducers of CYP3A
- •Prior or current anti-angiogenic therapy for patients with GBM. Radiation therapy within ≤ 4 weeks (< 12 for GBM) prior to the first dose of study drug or limited field radiotherapy within ≤ 2 weeks (< 12 weeks GBM) prior to the start of study treatment. Any persistent side effect of prior radiotherapy must be resolved to ≤ Grade 1 prior to the first dose of study drug.
- •Additional exclusion criteria for NSCLC patients EGFRwt with high c-MET expression:
- •Patients who have received more than three prior lines of antineoplastic therapies
- •Any unresolved toxicity (CTCAE grade > 1) from previous anti-cancer therapy or radiotherapy, except alopecia
- •Patients have received anti-cancer therapies within the following time frames prior to the first dose of study treatment:
- •Conventional cytotoxic chemotherapy: ≤4 weeks (≤6 weeks for nitrosoureas and mitomycin-C)
- •Biologic therapy (e.g., antibodies): ≤4 weeks
- •Non-cytotoxic small molecule therapeutics: ≤5 half-lives or ≤2 weeks (whichever is longer)
- •Other investigational agents: ≤4 weeks
- •Radiation therapy (palliative setting is allowed.): ≤4 weeks
- •Major surgery: ≤2 weeks
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究组 & 干预措施
INC280
Experimental
干预措施: INC280 (Drug)
结局指标
主要结局
Incidence rate of dose-limiting toxicities and adverse events
时间窗: 2 years
次要结局
- Objective response by local investigator assessment(2 years)
研究者
研究点 (6)
Loading locations...
相似试验
终止
1 期
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesSolid TumorsAdvanced MalignanciesMetastatic CancerNCT02265510Incyte Corporation83
进行中（未招募）
1 期
Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05537987InnoCare Pharma Inc.30
招募中
1 期
Safety of AM-928 Infusion in Advanced Solid TumorsAdvanced Solid TumorNCT05687682AcadeMab Biomedical Inc.38
招募中
1 期
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid TumorsHead and Neck CancerMalignant MelanomaColorectal CancerCervical CancerRenal Cell CarcinomaBreast CancerNCT06265025GeneMedicine Co., Ltd.125
已完成
1 期
A New Formulation of Calcitriol (DN-101) in Patients With Advanced MalignanciesNeoplasmsNCT00055263Novacea60